Triple-Drug attack before surgery shows promise in breast cancer trial

NCT ID NCT03573648

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times

Summary

This study tested whether giving a mix of hormone therapy, a targeted drug (palbociclib), and an immunotherapy (avelumab) before surgery could shrink early-stage estrogen receptor-positive breast tumors. About 33 adults with stage II-III breast cancer took part. The goal was to see how many patients had no cancer left at the time of surgery, and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Allegheny Health Network

Pittsburgh, Pennsylvania, 15224, United States
Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, 21287, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

Conditions

Explore the condition pages connected to this study.

BREAST CANCER